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In 2018, it was estimated that 1.6 million adolescents between the 
ages of 10 and 19 years, globally, were infected with HIV, accounting 
for 4% of all people living with HIV.[1] The United Nations Children’s 
Fund (UNICEF) reported that of the estimated 770 000 people who 
died of AIDS-related illnesses, 33 000 were adolescents, comprising 
4% of total deaths in 2018. Sub-Saharan Africa (SSA) has the highest 
number of HIV-infected adolescents (~1.5 million (89%)). It is 
estimated that 310 000 adolescents were living with HIV in South 
Africa (SA) in 2018, with 24 per 100 000 annual AIDS-related deaths.
An alarming trend over the past decade is the increase in AIDS-
related deaths among adolescents, which contrasts with the decrease 
in deaths among all other age groups.[2] Globally, AIDS-related deaths 
decreased by almost 40% between 2005 and 2013 for all age groups, 
except among adolescents (aged 10 - 19 years). HIV is the leading cause 
of adolescent mortality in SSA and the second highest worldwide.[3] 
In 2012, the leading cause of death in all age groups in SA was HIV/
AIDS: 50.7% among children (5 - 14 years) and 51.9% among adults 
(15 - 44 years).[4] The national household HIV study estimated that 
131 052 children (0 - 14 years) and 273 981 adolescents and young 
adults (15 - 24 years) had been exposed to antiretroviral therapy (ART) 
in 2017, and 51.9% and 47.7% had achieved viral load suppression 
(VLS), respectively.[5]
Although SSA has recorded comparably better adherence rates 
among adolescents on ART than other regions,[6] the main treatment 
outcome – VLS – remains unsatisfactory.[7-9] A meta-analysis of 8 studies 
in SA reported VLS among adolescents and young adults receiving 
ART as 81%.[10] Earlier studies conducted in SA reported VLS among 
adolescents at 12 months as 76% in selected public clinics in Gauteng 
and Mpumalanga provinces between 2004 and 2010; and 27% in a 
Cape Town-based ART clinic between 2002 and 2009.
Despite the poor treatment outcomes regarding VLS displayed 
by adolescents receiving ART, their situations are often overlooked 
because routine reporting in HIV programmes focus mainly on 
outcomes for paediatric (0 - 14 years) and adult (≥15 years) 
populations. Understanding treatment outcomes for adolescents (10 - 
19 years) is critical, because during this period patients are made 
aware of their HIV status (infected vertically), and have to learn to 
self-manage their disease (i.e. adhere to treatment regimens and 
attend clinic appointments) as they are transitioned to the adult HIV 
treatment programme. 
Objectives 
We report findings on 2-year treatment outcomes (VLS) of adolescent 
patients who were newly initiated on ART in public health facilities in 
the Metropole of Western Cape Province in 2013, and the risk factors 
associated with VLS at 4, 12 and 24 months after ART initiation.
Methods
Design 
We conducted a retrospective cohort analysis of adolescents aged 
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10 - 19 years, who were initiated on ART in 
2013 in public health facilities in the Western 
Cape Metropole. 
Participants
Data from 332 adolescent patients on ART 
from 29 facilities spread across the Western 
Cape Metropole were obtained from the 
provincial Tier.Net register. After cleaning 
the data, 220 adolescents were included 
in the final analysis. Of the 112 that were 
excluded, 68 medical records could not 
be found, despite numerous attempts at 
tracing these documents at the various 
facilities. Furthermore, 28 patients were 
incorrectly captured as new patients (when 
they were transferred from other facilities); 
4 patients were not adolescents (dates of 
birth incorrectly captured); and 12 patients 
had been incorrectly captured as having 
initiated ART in 2013. Fig. 1 illustrates the 
sampling process. 
Main outcome measures and 
analysis
We extracted data on sociodemographic 
characteristics (age, sex, source of income, 
type of dwelling, disclosure to significant 
other and reported alcohol or other drug 
use) and clinical characteristics (CD4 count, 
World Health Organization (WHO) clinical 
stage, tuberculosis (TB) treatment, being 
pregnant, isoniazid preventive therapy (IPT), 
co-trimoxazole use and ART regimen).
Bivariate analysis was conducted to 
determine the significance and strength 
of associations between VLS at 4, 12 and 
24 months and various sociodemographic 
(age, sex and being pregnant) and clinical 
characteristics (WHO staging). Statistical 
significance was established using the 
χ2 test (with significance set at p<0.05) 
and where significance was observed, 
strength of associations was calculated as 
risk ratios with 95% confidence intervals 
(CIs), using SPSS version 26 (IBM Corp., 
USA).
Ethical approval
The protocol was approved by the University 
of the Western Cape Biomedical Research 
Ethics Committee (ref. no. BM/17/1/15) 
and the Western Cape Government Health 
Impact Assessment Committee (ref. no. 
WC_2017RP58_418). Permission to access 
patients’ clinical records from the various 
healthcare facilities was obtained from the 
facility managers. No informed consent was 
required, as there was no direct contact 
with patients and no patient identifiers were 
collected.
Results
Of the 220 patients who were newly initiated 
on ART in 2013, the majority were older 
adolescents (15 - 19 years) (n=179; 81.4%) 
and female (n=182; 82.7%) (Table 1). Most 
adolescents included in the study received 
financial support from their families and 
friends (n=129; 58.6%) and lived in a 
formal house (n=116; 52.7%). In line with 
the HIV clinical treatment guidelines, the 
overwhelming majority (n=182; 87%) had 
disclosed their HIV status to a significant 
other, or in the case of younger adolescents, 
HIV status had been disclosed to them.
The median CD4 count at ART initiation 
was 292.5 cells/µL (interquartile range (IQR) 
228.8 - 391.3). No baseline CD4 count had 
been recorded for 2 participants. Half of the 
participants (n=109) had CD4 counts of 200 - 
349 cells/µL, and 19% (n=42) had baseline 
CD4 counts <200 cells/µL. 
Of the 213 participants who had WHO 
staging done at ART initiation, 46.5% and 
22.5% were WHO stage I and II, respectively; 
and 23.2% and 6.8% were WHO stage III 
and IV, respectively.
Loss to follow-up was considerable, 
with only 151 (68.6%), 111 (50.5%) and 80 
(36.4%) retained in care at 4, 12 and 24 months 
after initiation, respectively.
VLS was low throughout the study period, 
with 131 (59.5%), 88 (40%) and 55 (25%) 
adolescents having recorded VLS at 4, 12 and 
24 months after ART initiation, respectively. 
Fig. 2 illustrates the comparison of VLS at 
4, 12 and 24 months post-initiation VLS for 
all adolescents compared with those who 
remained in care at the various time points 
Adolescents initiated on ART, who were
transferred from another facility, were excluded
Provincial Tier.Net database, including all
patients initiated on ART in the Western Cape
All patients on ART in the Metro District 
Health Services of the Western Cape
All adolescents (10 - 19 years old) initiated 
on ART from 1 January to 31 December 2013
Adolescents initiated on ART at the Metro
District Health Services facilities in 2013
Fig. 1. Sampling process. (ART = antiretroviral therapy.)
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Fig. 2. Comparison of viral load suppression in all adolescents v. those retained in care. (ALL = all; 
RIC = retained in care.)
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as 59.5% v. 86.8%, 40% v. 79.3% and 25% v. 68.8%, respectively. 
Therefore, VLS was significantly associated with retention in care. 
However, VLS fell short of the targeted 90% throughout the study 
observation period.
Table 1. Characteristics of adolescents initiated on ART with viral load suppression at Metro District Health Services facilities in 
the Western Cape, South Africa, 2013
Characteristics N (%)
            Month 4           Month 12 Month 24
n (%) p-value n (%) p-value n (%) p-value
Age, years
10 - 14 41 (18.6) 29 (70.7) 0.106 26 (63.4) 0.001* 24 (58.5) <0.001*
15 - 19 179 (81.4) 102 (57.0) 62 (34.6) 31 (17.3)
Sex
Male 38 (17.3) 31 (81.6) 0.002* 21 (55.3) 0.035* 18 (47.4) <0.001*
Female 182 (82.7) 100 (54.9) 67 (36.8) 37 (20.3)
Source of income
Employed 15 (9.4) 10 (66.7) 0.141 5 (33.3) 0.365 2 (13.3) 0.003*
Family and friends 129 (80.6) 73 (56.6) 51 (39.5) 25 (19.4)
Grant 16 (10.0) 13 (81.3) 9 (5.6) 9 (5.6)
Type of dwelling
Informal 69 (36.1) 42 (60.9) 0.288 27 (39.1) 0.454 14 (20.3) 0.589
Formal house 116 (60.7) 64 (55.2) 43 (37.1) 27 (23.3)
Hostel 4 (2.1) 1 (25.0) 0 0
Other 2 (1.1) 2 (100) 1 (50) 0
Disclosure to significant other
Yes 182 (87.1) 108 (59.3) 0.709 76 (41.8) 0.117 49 (26.9) 0.076
No 27 (12.9) 15 (55.6) 7 (25.9) 3 (11.1)
Reported alcohol and/or drug use
Yes 27 (15) 16 (59.3) 0.721 10 (37.0) 0.913 4 (14.8) 0.510
No 153 (85) 85 (55.6) 55 (35.9) 31 (20.3)
CD4 count, cells/µL
<200 42 (19.3) 24 (57.1) 0.703 18 (42.9) 0.816 14 (33.3) 0.262
200 - 349 109 (50.0) 64 (58.7) 45 (41.3) 28 (25.7)
≥350 67 (30.7) 43 (64.2) 25 (37.3) 13 (19.4)
WHO stage
I 99 (46.5) 51 (51.5) 0.081 35 (35.4) 0.441 15 (15.2) 0.020*
II 48 (22.5) 30 (62.5) 22 (45.8) 15 (31.3)
III 51 (23.9) 37 (72.5) 20 (39.2) 17 (33.3)
IV 15 (7.0) 10 (66.7) 8 (53.3) 6 (40.0)
TB treatment
Yes 31 (14.1) 23 (74.2) 0.073 15 (48.4) 0.304 11 (35.5) 0.146
No 189 (85.9) 108 (57.1) 73 (38.6) 44 (23.3)
Pregnant
Yes 84 (38.2) 39 (46.4) 0.002* 25 (29.8) 0.015*  7 (8.3) <0.001*
No 136 (61.8) 92 (67.6) 63 (46.3) 48 (35.3)
IPT
Yes 15 (6.8) 8 (53.3) 0.492 5 (33.3) 0.826 2 (13.3) 0.184
No 165 (73.2) 96 (58.2) 66 (40.0) 39 (23.6)
Co-trimoxazole
Yes 84 (38.2) 55 (65.5) 0.203 38 (45.2) 0.437 30 (35.7) 0.010*
No 51 (61.8) 26 (50.0) 20 (38.5) 12 (23.1)
ART regimen
TFE 157 (71.4) 88 (56.1) 0.296 54 (34.4) 0.019* 25 (15.9) <0.001*
T3E 27 (12.3) 16 (59.3) 11 (40.7) 7 (25.9)
A3E 34 (15.5) 25 (73.5) 21 (61.8) 22 (64.7)
Z3E 1 (0.4) 1 (100) 1 (100) 0
T3L/rit 1 (0.4) 1 (100) 1 (100) 1 (100)
ART = antiretroviral therapy; WHO = World Health Organization; TB = tuberculosis; IPT = isoniazid preventive therapy; TFE = tenofovir + emtricitabine + efavirenz; 
T3E = tenofovir+lamivudine+efavirenz; A3E = abacavir+lamivudine+efavirenz; 
Z3E = zidovudine + lamivudine + efavirenz; T3L/rit = tenofovir + lamivudine + lopinovir/ritonavir.
*Statistical significance set at p<0.05. 
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Table 2 shows that younger adolescents (10 - 14 years) had a higher 
risk of VLS at 12 and 24 months post initiation on ART than older 
adolescents (15 - 19 years). At 12 months post initiation on ART, 
younger adolescents had an 83% higher risk of VLS (risk ratio (RR) 
1.83 (95% CI 1.35 - 2.49)) than older adolescents; and >3 times higher 
risk (RR 3.38 (95% CI 2.24 - 5.10)) at 24 months.
Male adolescents had a higher risk of VLS at 4 months (RR 1.49 
(95% CI 1.22 - 1.81)), 12 months (RR 1.5 (95% CI 1.07 - 2.12)) 
and 24 months (RR 2.33 (1.50 - 3.62)) post initiation than female 
adolescents. 
Adolescents who were pregnant had a significantly lower risk of 
VLS than all other adolescents (RR 0.69 (95% CI 0.53 - 0.89)) at 
6 months; RR 0.64 (95% CI 0.44 - 0.94) at 12 months; and RR 0.24 (at 
all the observed time points).
There was no statistically significant difference in achieving VLS at 
4 and 12 months post initiation among adolescents, based on WHO 
staging at initiation. However, there was a statistically significant 
difference in VLS at 24 months post initiation on treatment for 
adolescents who were classified as WHO stage I at initiation 
compared with those classified as WHO stage II, III or IV (p=0.020). 
At 24 months post-ART initiation, those who were at WHO stage II 
at initiation had a 52% higher risk of VLS (RR 1.52 (95% CI 1.09 - 
1.74)), those who were WHO stage III ‒ 55% (RR 1.55 (95% CI 1.17 
- 1.75)) and those who were WHO stage IV ‒ 62% (RR 1.62 (95% 
CI 1.18 - 1.83)) compared with those who were initiated on ART at 
WHO stage I. 
Discussion
In 2014, the WHO set a global target of 90-90-90, which required 
that by 2020, 90% of all people living with HIV are diagnosed, 90% 
of those diagnosed are initiated on ART, and 90% of those on ART 
achieve viral suppression.[11] Our study cohort fell short of this target 
throughout the observation period, with rates of 59.5%, 40.0% and 
25.0% at month 4, 12 and 24 post initiation, respectively. Even among 
those retained in care, VLS rates were unsatisfactory, i.e. 86.8%, 79.3% 
and 68.8% at month 4, 12 and 24 post initiation, respectively. These 
results indicate poor ART adherence of adolescents, in addition to the 
significant loss to follow-up. Our results follow the trends reported 
elsewhere in SSA and other regions,[8] giving further credence to the 
global importance of addressing unsatisfactory treatment outcomes 
for adolescents receiving ART.
Older adolescents (15 - 19 years) were observed to have lower 
rates of VLS than younger adolescents. This is an important finding, 
and emphasises that adolescents experience significant adherence 
problems when transitioning into adult HIV programmes. Although 
very few facilities in the Western Cape provide separate paediatric 
and adult treatment programmes, adolescent patients are treated 
differently once their HIV status has been disclosed to them, and 
they are expected to self-manage their HIV condition (as an adult). 
There are very few youth clubs for adolescents and young people 
in the Western Cape Metropole. Where these are offered, limited 
psychosocial support is effectively delivered as part of the service; 
and these become de facto quick medication pick-up services only.
A surprising finding from our study was that male adolescents had 
higher rates of VLS than females. It should be noted that only 46% of 
female adolescents were initiated on ART while pregnant as part of the 
prevention of mother-to-child transmission (PMTCT) programme. 
Their rates of VLS were consistently lower compared with all other 
adolescents; at 24 months, only 8% had VLS. This finding concurs 
with findings in other studies, where adherence, retention in care 
and VLS decrease significantly after 12 months, which corresponds 
to the completion of the immunisation schedule for an infant. The 
PMTCT programme booking provides opportunities to support 
the pregnant adolescent to achieve favourable outcomes for her and 
her baby. These opportunities include having a longer time period 
to educate the patient on HIV and ART, as well as identifying and 
assisting with any barriers to poor adherence, including disclosure 
or socioeconomic challenges. Early antenatal care booking becomes 
increasingly important in the context of the Western Cape ART 
guidelines that encourage same-day ART initiation for pregnant 
HIV-infected women.[12] 
Adolescents in our study who were initiated at higher WHO stages 
(II, III and IV) at baseline had higher rates of VLS, although this did 
not reach statistical significance, except at month 24. Therefore, just 
fewer than half of the cohort did not feel particularly ill when they 
were enrolled on ART, and were therefore not motivated by ill-health 
to remain fully adherent and engaged in care. With the introduction 
of universal coverage for HIV-infected individuals, irrespective of 
Table 2. Rate of viral load suppression among adolescents initiated on ART in Metro District Health Services facilities in the Western Cape, 
South Africa, 2013 (N=220)
        Month 4        Month 12         Month 24
RR (95% CI) RR (95% CI) RR (95% CI)
Age, years
10 - 14 1.24 (0.98 - 1.57) 1.83 (1.35 - 2.49) 3.38 (2.24 - 5.10)
15 - 19 1.00 1.00 1.00
Sex
Male 1.49 (1.22 - 1.81) 1.50 (1.07 - 2.12) 2.33 (1.50 - 3.62)
Female 1.00 1.00 1.00
WHO stage
I 1.00 1.00 1.00
II 1.18 (0.90 - 1.38) 1.23 (0.84 - 1.49) 1.52 (1.09 - 1.74)
III 1.29 (1.08 - 1.45) 1.10 (0.61 - 1.42) 1.55 (1.17 - 1.75)
IV 1.23 (0.84 - 1.49) 1.34 (0.86 - 1.62) 1.62 (1.18 - 1.83)
Pregnant
Yes 0.69 (0.53 - 0.89) 0.64 (0.44 - 0.94) 0.24 (0.11 - 0.50)
No 1.00 1.00 1.00
ART = antiretroviral therapy; RR = risk ratio; CI = confidence interval; WHO = World Health Organization.
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WHO staging or CD4 count,[12] relatively healthier people will be 
initiating ART, resulting in the potential risk of healthier people not 
being motivated to remain in care, as reported in another study.[13] 
Therefore, the ART programme needs to scale up efforts to motivate 
patients to remain in care and continue taking their medication to 
achieve VLS. 
Study limitations
There are some important clinical parameters, such as comorbidities, 
duration of infection (diagnosis) and mode of acquisition of HIV 
that are covariates for the outcome measure of VLS, which were 
not obtained from medical records, as these were poorly and 
inconsistently captured.
Conclusions
All adolescents in our study had viral loads taken and recorded 
while they remained in care – this speaks to a measure of quality 
of care being provided in public health facilities in the Western 
Cape Metropole. Our study highlights the low rates of VLS among 
adolescents, which deserve urgent attention to improve adherence 
and retention in care for adolescents. Such interventions should 
address the unique needs of older adolescents and adolescents who 
initiate ART while pregnant. Behavioural interventions to improve 
adherence should include positive messaging about health and well-
being, rather than the prevention of illness and death.
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